These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 8049708

  • 1. Clinical trials to treat the underlying cause of emphysema.
    Cohen AB.
    Monaldi Arch Chest Dis; 1994 Apr; 49(2):95-7. PubMed ID: 8049708
    [No Abstract] [Full Text] [Related]

  • 2. [Elastase, elastase inhibitors and chronic obstructive lung diseases].
    Kramps JA, Dijkman JH.
    Ned Tijdschr Geneeskd; 1990 Jun 09; 134(23):1127-30. PubMed ID: 2192289
    [No Abstract] [Full Text] [Related]

  • 3. Opportunities for the development of specific therapeutic agents to treat emphysema.
    Cohen AB.
    Am Rev Respir Dis; 1979 Oct 09; 120(4):723-7. PubMed ID: 389114
    [No Abstract] [Full Text] [Related]

  • 4. [Possibilities of the prevention and treatment of pulmonary emphysema in the light of the "proteolytic" theory of its pathogenesis].
    Nowak D.
    Pneumonol Pol; 1985 Oct 09; 53(10):492-6. PubMed ID: 3912732
    [No Abstract] [Full Text] [Related]

  • 5. [Cigarette smoking and the etiopathogenesis of pulmonary emphysema].
    Górecka D.
    Pneumonol Pol; 1984 Jul 09; 52(7):353-7. PubMed ID: 6387638
    [No Abstract] [Full Text] [Related]

  • 6. Letter: Familial variation of leukocyte lysosomal protease and serum alpha 1-antitrypsin as determinants in chronic obstructive pulmonary disease.
    Galdston M, Davis AL, Janoff A.
    Am Rev Respir Dis; 1973 Oct 09; 108(4):1020-1. PubMed ID: 4542641
    [No Abstract] [Full Text] [Related]

  • 7. Design of a clinical trial to test a treatment of the underlying cause of emphysema.
    Anthonisen N, Connett J, Friedman B, Glass M, Kilday DP, Mingo TS, Rudolphus A, Williams GW.
    Ann N Y Acad Sci; 1991 Dec 31; 624 Suppl():31-4. PubMed ID: 1686163
    [No Abstract] [Full Text] [Related]

  • 8. Letter: Familial variation of leukocyte lysosomal protease and serum alpha 1-antitrypsin as determinants in chronic obstructive pulmonary diseases.
    Leiberman J.
    Am Rev Respir Dis; 1973 Oct 31; 108(4):1019-20. PubMed ID: 4542640
    [No Abstract] [Full Text] [Related]

  • 9. [Role of certain mechanisms in the pathogenesis of emphysema and a number of other lung diseases].
    Putov NV, Pokhodzeĭ IV, Kolodkina LA.
    Ter Arkh; 1985 Oct 31; 57(3):144-8. PubMed ID: 3890255
    [No Abstract] [Full Text] [Related]

  • 10. Selection of a therapeutic agent for the treatment of chronic obstructive pulmonary disease in smokers.
    Turino GM, Davies P, Dunlap R, Krell RD, Maycock AL, Rennard S, Stockley RA.
    Ann N Y Acad Sci; 1991 Dec 31; 624 Suppl():23-30. PubMed ID: 1686162
    [No Abstract] [Full Text] [Related]

  • 11. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema.
    Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT, Crystal RG.
    N Engl J Med; 1987 Apr 23; 316(17):1055-62. PubMed ID: 3494198
    [Abstract] [Full Text] [Related]

  • 12. The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivo.
    Carter RI, Mumford RA, Treonze KM, Finke PE, Davies P, Si Q, Humes JL, Dirksen A, Piitulainen E, Ahmad A, Stockley RA.
    Thorax; 2011 Aug 23; 66(8):686-91. PubMed ID: 21617168
    [Abstract] [Full Text] [Related]

  • 13. The potential role of elastase inhibitors in emphysema treatment.
    Eriksson S.
    Eur Respir J; 1991 Oct 23; 4(9):1041-3. PubMed ID: 1684550
    [No Abstract] [Full Text] [Related]

  • 14. Alpha1-antitrypsin deficiency (second of two parts).
    Morse JO.
    N Engl J Med; 1978 Nov 16; 299(20):1099-105. PubMed ID: 360065
    [No Abstract] [Full Text] [Related]

  • 15. [The evolution of the replacement treatment of emphysema due to alpha 1-antitrypsin deficiency].
    Manresa F.
    Arch Bronconeumol; 1995 Nov 16; 31(7):371-2. PubMed ID: 8777536
    [No Abstract] [Full Text] [Related]

  • 16. [Pathogenetic significance of alpha 1 antitrypsin in chronic-obstructive respiratory tract diseases].
    Geisler LS, Rost HD, Bachmann GW, Vogel F.
    Pneumonologie; 1975 Sep 26; 152(1-3):93-104. PubMed ID: 1081220
    [No Abstract] [Full Text] [Related]

  • 17. Alpha-1 antitrypsin: now available, but do we need it?
    Russi EW.
    Swiss Med Wkly; 2008 Apr 05; 138(13-14):191-6. PubMed ID: 18389391
    [Abstract] [Full Text] [Related]

  • 18. Functional assay of alpha 1-antitrypsin in obstructive lung disease.
    Billingsley GD, Cox DW.
    Am Rev Respir Dis; 1980 Jan 05; 121(1):161-4. PubMed ID: 6965439
    [Abstract] [Full Text] [Related]

  • 19. Are There Differences Between the Available Treatments for Emphysema Associated with Alpha-1 Antitrypsin Deficiency?
    Esquinas C, Miravitlles M.
    Arch Bronconeumol (Engl Ed); 2018 Sep 05; 54(9):451-452. PubMed ID: 29625713
    [No Abstract] [Full Text] [Related]

  • 20. Augmentation therapy of alpha-1 antitrypsin deficiency associated emphysema.
    Traclet J, Delaval P, Terrioux P, Mornex JF.
    Rev Mal Respir; 2015 Apr 05; 32(4):435-46. PubMed ID: 25908241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.